Scientists scan fat to unlock secrets of popular Weight-Loss drug
NCT ID NCT07187830
Summary
This study aims to understand how the medication semaglutide (a drug for diabetes and weight loss) affects fat stored around vital organs like the heart, liver, and kidneys in people who have both type 2 diabetes and chronic kidney disease. Researchers will use MRI scans to measure this fat in about 52 participants, some taking semaglutide and some not. The goal is to learn how changes in this fat might relate to kidney health, which could inform future treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mazankowski Alberta Heart Institute
Edmonton, Alberta, T6G 2B7, Canada
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.